BeyondSpring (NASDAQ:BYSI) versus TG Therapeutics (NASDAQ:TGTX) Head-To-Head Contrast

BeyondSpring (NASDAQ:BYSI) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Valuation and Earnings

This table compares BeyondSpring and TG Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BeyondSpring $180,000.00 3,337.05 -$60.97 million ($2.03) -7.57
TG Therapeutics $150,000.00 28,953.78 -$279.38 million ($2.42) -12.69

BeyondSpring has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for BeyondSpring and TG Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeyondSpring 0 0 5 0 3.00
TG Therapeutics 0 1 3 0 2.75

BeyondSpring currently has a consensus target price of $58.75, suggesting a potential upside of 282.49%. TG Therapeutics has a consensus target price of $69.25, suggesting a potential upside of 125.57%. Given BeyondSpring’s stronger consensus rating and higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than TG Therapeutics.

Profitability

This table compares BeyondSpring and TG Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BeyondSpring N/A -114.10% -80.98%
TG Therapeutics -14,271.13% -90.75% -71.42%

Institutional & Insider Ownership

19.1% of BeyondSpring shares are owned by institutional investors. Comparatively, 67.1% of TG Therapeutics shares are owned by institutional investors. 10.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

BeyondSpring has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500.

Summary

BeyondSpring beats TG Therapeutics on 8 of the 14 factors compared between the two stocks.

BeyondSpring Company Profile

BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. It operates through PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

TG Therapeutics Company Profile

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.